Clinical Trial: ARV-471 or Anastrozole in ER+, HER2- Localized Breast Cancer
Researchers are conducting a phase 2 trial to test ARV-471 or anastrozole in patients with ER+, HER2- localized breast cancer.
Researchers are conducting a phase 2 trial to test ARV-471 or anastrozole in patients with ER+, HER2- localized breast cancer.
MRI is the best supplemental imaging modality for detecting breast cancer in women with dense breasts and negative mammography, a meta-analysis suggests.
Adding docetaxel to radiation improves outcomes for cisplatin-ineligible patients with locally advanced head and neck squamous cell carcinoma, a phase 2/3 trial suggests.
Oncology trial reports written by medical writers are more likely to have surrogate endpoints as the primary endpoint.
Certain patients with resected renal cell carcinoma may benefit from adjuvant treatment with immune checkpoint inhibitors, a meta-analysis suggests.
Adding ganitumab to standard chemotherapy does not provide a benefit for patients with metastatic Ewing sarcoma, a phase 3 trial suggests.
The risk of early death in AYAs with cancer depends on the type of malignancy they have as well as multiple demographic factors, a study suggests.
NSAIDs may improve the efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer, a study suggests.
Centers that perform comprehensive cancer screening in a single appointment may enable earlier cancer diagnosis.